Cardiol Therapeutics’ (CRDL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Cardiol Therapeutics (TSE:CRDL) in a report released on Monday, BayStreet.CA reports.

Cardiol Therapeutics Stock Down 3.6 %

Shares of Cardiol Therapeutics stock opened at C$2.40 on Monday. The company has a quick ratio of 6.84, a current ratio of 5.29 and a debt-to-equity ratio of 0.52. Cardiol Therapeutics has a 12 month low of C$0.74 and a 12 month high of C$2.94. The business has a fifty day simple moving average of C$2.30 and a 200 day simple moving average of C$1.62. The stock has a market cap of C$156.26 million, a PE ratio of -5.58 and a beta of 0.75.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.